{"id":42174,"date":"2018-06-18T21:03:41","date_gmt":"2018-06-18T19:03:41","guid":{"rendered":"https:\/\/newserver.fyb.de\/2-6-million-euros-for-medtech-company-fasciotens\/"},"modified":"2018-06-18T21:03:41","modified_gmt":"2018-06-18T19:03:41","slug":"2-6-million-euros-for-medtech-company-fasciotens","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/","title":{"rendered":"2.6 million euros for medtech company Fasciotens"},"content":{"rendered":"<p>Essen \u2014 The <strong>Gr\u00fcn\u00adder\u00adfonds Ruhr, initia\u00adted<\/strong> jointly by <strong>NRW.BANK<\/strong> and <strong>Initia\u00adtiv\u00adkreis<\/strong> <strong>Ruhr<\/strong>, has made its first invest\u00adment. As part of a Series A finan\u00adcing, he has inves\u00adted around 2.6 million euros in<strong> Fascio\u00adtens<\/strong> GmbH toge\u00adther with the VC inves\u00adtor<strong> copa\u00adrion<\/strong>. The Essen-based medi\u00adcal tech\u00adno\u00adlogy company has deve\u00adlo\u00adped an inno\u00adva\u00adtive therapy for open abdomens.<\/p>\n<p>\u201cFascio\u00adtens is Gr\u00fcn\u00adder\u00adfonds Ruhr\u2019s first invest\u00adment and a perfect exam\u00adple of young and inno\u00adva\u00adtive medi\u00adcal tech\u00adno\u00adlogy busi\u00adness ideas that can thrive in the Ruhr region,\u201d says <strong>Dr. Aris\u00adto\u00adte\u00adlis Nastos<\/strong>, one of the two mana\u00adging direc\u00adtors of Gr\u00fcn\u00adder\u00adfonds&nbsp;Ruhr.<\/p>\n<p>Dr. Sebas\u00adtian P\u00fcnze\u00adler, Invest\u00adment Mana\u00adger at copa\u00adrion, added: \u201cFascio\u00adtens was deve\u00adlo\u00adped by prac\u00adti\u00adcing surge\u00adons for surge\u00adons and will signi\u00adfi\u00adcantly improve medi\u00adcal care for high-risk open abdo\u00admen pati\u00adents, simul\u00adta\u00adneously redu\u00adcing the length of stay of pati\u00adents in the inten\u00adsive care&nbsp;unit.\u201d<\/p>\n<p>The new therapy \u201cFascio\u00adtens Abdo\u00admen\u201d was deve\u00adlo\u00adped by the foun\u00adders and mana\u00adging direc\u00adtors of Fascio\u00adtens GmbH, the surge\u00adons<strong> Dr. Gereon Lill <\/strong>and<strong> Dr. Frank Beyer<\/strong>. They have deve\u00adlo\u00adped a device that atta\u00adches extern\u00adally to the abdo\u00admi\u00adnal wall and keeps the abdo\u00admi\u00adnal wall fasciae in a state of tension. Thus, they provide a solu\u00adtion to the surgi\u00adcal problem of abdo\u00admi\u00adnal closure after an open abdo\u00admen. Pati\u00adents with life-threa\u00adtening illnesses can thus be trea\u00adted with good success. In addi\u00adtion to impro\u00adved pati\u00adent care, the use of this novel therapy results in a signi\u00adfi\u00adcant reduc\u00adtion in treat\u00adment&nbsp;costs.<br>\nIn the future, the proce\u00addure will also be used in infants with a conge\u00adni\u00adtal abdo\u00admi\u00adnal wall defect.<\/p>\n<p>For the two mana\u00adging direc\u00adtors, the invest\u00adment is a stroke of&nbsp;luck.<br>\n\u201cThe parti\u00adci\u00adpa\u00adtion of Gr\u00fcn\u00adder\u00adfonds Ruhr and copa\u00adrion in the amount of appro\u00adxi\u00adm\u00adately 2.6 million euros enables us to rapidly advance CE appr\u00adoval and the first clini\u00adcal appli\u00adca\u00adtion study, and to prepare the market entry of the first product,\u201d says Dr. Frank Beyer. \u201cIn addi\u00adtion, funding will also be made available for the deve\u00adlo\u00adp\u00adment of other products.\u201d<\/p>\n<p>\u201cToge\u00adther with the inves\u00adtors, we have estab\u00adlished concrete mile\u00adsto\u00adnes and are bene\u00adfiting from the expe\u00adri\u00adence and network of our inves\u00adtors in the still young phase of our company,\u201d adds Dr. Gereon Lill.<\/p>\n<p>The new therapy is also well recei\u00adved in practice.<br>\nProf. Dr. Kriegl\u00adstein, Chief Physi\u00adcian of the Surgi\u00adcal Clinic at St. Elisa\u00adbeth Hospi\u00adtal Colo\u00adgne-Hohen\u00adlind, explains: \u201cThe idea origi\u00adna\u00adted in surgi\u00adcal prac\u00adtice and is convin\u00adcing in its simpli\u00adcity. Due to the seve\u00adrity of the dise\u00adase, the treat\u00adment form meets an immense medi\u00adcal&nbsp;need.\u201d<\/p>\n<p>Photo (from left): Dr. Sebas\u00adtian P\u00fcnze\u00adler (copa\u00adrion), Dr. Gereon Lill and Dr. Frank Beyer (both Fascio\u00adtens), Dr. Aris\u00adto\u00adte\u00adlis Nastos (Gr\u00fcn\u00adder\u00adfonds&nbsp;Ruhr).<br>\nSource: Initia\u00adtiv\u00adkreis Ruhr\/reprint free of charge<\/p>\n<p><strong>About the Gr\u00fcn\u00adder\u00adfonds&nbsp;Ruhr<\/strong><br>\nThe Gr\u00fcn\u00adder\u00adfonds was initia\u00adted jointly by Initia\u00adtiv\u00adkreis Ruhr and NRW.BANK and is the first private-sector early-stage fund in the Ruhr region finan\u00adced by regio\u00adnal indus\u00adtrial and finan\u00adcial compa\u00adnies. The fund invests in inno\u00adva\u00adtive and tech\u00adno\u00adlogy-orien\u00adted compa\u00adnies from the life science &amp; health, digi\u00adtal economy, chemi\u00adcals &amp; new mate\u00adri\u00adals, energy &amp; indus\u00adtry, and logi\u00adstics &amp; trade sectors. Prere\u00adqui\u00adsi\u00adtes are good growth and exit pros\u00adpects as well as compe\u00adtent manage\u00adment. As a multi-corpo\u00adrate early-stage fund, it also opens up important indus\u00adtry access points for the respec\u00adtive port\u00adfo\u00adlio compa\u00adnies. www.gruenderfonds-ruhr.com<\/p>\n<p><strong>About copa\u00adrion<\/strong><br>\ncopa\u00adrion is a venture capi\u00adtal inves\u00adtor for young, German tech\u00adno\u00adlogy compa\u00adnies. With a fund volume of 225 million euros, copa\u00adrion is making a signi\u00adfi\u00adcant contri\u00adbu\u00adtion to rapid and sustainable growth. copa\u00adrion supports entre\u00adpre\u00adneu\u00adrial vision with know-how without inter\u00adfe\u00adring in the opera\u00adtio\u00adnal busi\u00adness. With many years of expe\u00adri\u00adence in venture capi\u00adtal and in buil\u00adding up compa\u00adnies, the copa\u00adrion team reco\u00adgni\u00adzes poten\u00adtial and opens up new perspec\u00adti\u00adves. copa\u00adrion brings the subs\u00adtance, perse\u00adver\u00adance and crea\u00adti\u00advity to successfully master even diffi\u00adcult situa\u00adtions toge\u00adther. copa\u00adrion finan\u00adces exclu\u00adsi\u00advely toge\u00adther with co-inves\u00adtors. The focus is on the start-up and young growth phase. The fund invests up to \u20ac10 million per company, usually in seve\u00adral finan\u00adcing rounds of \u20ac0.5\u20135 million each. Copa\u00adrion has offices in Colo\u00adgne and Berlin.<\/p>\n<p><strong>About Fascio\u00adtens<\/strong><br>\nFascio\u00adtens GmbH, based in Essen, Germany, was foun\u00added in 2016 by Dr. Gereon Lill and Dr. Frank Beyer. It deve\u00adlops inno\u00adva\u00adtive products for surgery. The foun\u00adders place parti\u00adcu\u00adlar empha\u00adsis on direct cont\u00adact with users in the clinics, which takes place on an equal footing due to their many years of medi\u00adcal practice.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Essen \u2014 The Gr\u00fcn\u00adder\u00adfonds Ruhr, initia\u00adted jointly by NRW.BANK and Initia\u00adtiv\u00adkreis Ruhr, has made its first invest\u00adment. As part of a Series A finan\u00adcing, he has inves\u00adted around 2.6 million euros in Fascio\u00adtens GmbH toge\u00adther with the VC inves\u00adtor copa\u00adrion. The Essen-based medi\u00adcal tech\u00adno\u00adlogy company has deve\u00adlo\u00adped an inno\u00adva\u00adtive therapy for open abdo\u00admens. \u201cFascio\u00adtens&nbsp;is&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42185,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1366],"tags":[],"class_list":["post-42174","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-news-en","news-category-venture-capital-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>2.6 million euros for medtech company Fasciotens - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2.6 million euros for medtech company Fasciotens - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Essen \u2014 The Gr\u00fcn\u00adder\u00adfonds Ruhr, initia\u00adted jointly by NRW.BANK and Initia\u00adtiv\u00adkreis Ruhr, has made its first invest\u00adment. As part of a Series A finan\u00adcing, he has inves\u00adted around 2.6 million euros in Fascio\u00adtens GmbH toge\u00adther with the VC inves\u00adtor copa\u00adrion. The Essen-based medi\u00adcal tech\u00adno\u00adlogy company has deve\u00adlo\u00adped an inno\u00adva\u00adtive therapy for open abdomens. \u201cFascio\u00adtens is [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-18T19:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"290\" \/>\n\t<meta property=\"og:image:height\" content=\"174\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"2.6 million euros for medtech company Fasciotens\",\"datePublished\":\"2018-06-18T19:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/\"},\"wordCount\":704,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png\",\"articleSection\":[\"General\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/\",\"url\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/\",\"name\":\"2.6 million euros for medtech company Fasciotens - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png\",\"datePublished\":\"2018-06-18T19:03:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png\",\"width\":290,\"height\":174},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2.6 million euros for medtech company Fasciotens\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2.6 million euros for medtech company Fasciotens - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/","og_locale":"en_US","og_type":"article","og_title":"2.6 million euros for medtech company Fasciotens - FYB Financial Yearbook","og_description":"Essen \u2014 The Gr\u00fcn\u00adder\u00adfonds Ruhr, initia\u00adted jointly by NRW.BANK and Initia\u00adtiv\u00adkreis Ruhr, has made its first invest\u00adment. As part of a Series A finan\u00adcing, he has inves\u00adted around 2.6 million euros in Fascio\u00adtens GmbH toge\u00adther with the VC inves\u00adtor copa\u00adrion. The Essen-based medi\u00adcal tech\u00adno\u00adlogy company has deve\u00adlo\u00adped an inno\u00adva\u00adtive therapy for open abdomens. \u201cFascio\u00adtens is [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2018-06-18T19:03:41+00:00","og_image":[{"width":290,"height":174,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png","type":"image\/png"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"2.6 million euros for medtech company Fasciotens","datePublished":"2018-06-18T19:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/"},"wordCount":704,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png","articleSection":["General","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/","url":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/","name":"2.6 million euros for medtech company Fasciotens - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png","datePublished":"2018-06-18T19:03:41+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/06\/a-coparion-3.png","width":290,"height":174},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/2-6-million-euros-for-medtech-company-fasciotens\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"2.6 million euros for medtech company Fasciotens"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42174"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42174\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42185"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}